Table 1.
Patient characteristics at diagnosis (n = 324)
| Parameters | Total | RCHOP | RCVP | BR | P-value |
|---|---|---|---|---|---|
| 324 (100) | 111 (34.3) | 152 (46.9) | 61 (18.8) | ||
| Age (n, %) | |||||
| ≤ 60 | 254 (78.4) | 88 (79.3) | 121 (79.6) | 45 (73.8) | 0.62 |
| > 60 | 70 (21.6) | 23 (20.7) | 31 (20.4) | 16 (26.2) | |
| Sex (n, %) | |||||
| Male | 161 (49.7) | 62 (55.9) | 72 (47.4) | 27 (44.3) | 0.26 |
| Female | 163 (50.3) | 49 (44.1) | 80 (52.6) | 34 (55.7) | |
| ECOG PS (n, %) | |||||
| 0/1 | 313 (96.6) | 108 (97.3) | 146 (96.1) | 59 (96.7) | 0.86 |
| ≥ 2 | 11 (3.4) | 3 (2.7) | 6 (3.9) | 2 (3.3) | |
| B-symptom (n, %) | 26 (9.6) | 11 (9.9) | 12 (7.9) | 3 (4.9) | 0.65 |
| Anemia < 12 g/dL (n, %) | 52 (16.0) | 22 (19.8) | 19 (12.5) | 11 (18.0) | 0.25 |
| Elevated LDH (n, %) | 60 (18.5) | 25 (22.5) | 23 (15.1) | 12 (19.7) | 0.30 |
| Elevated β2-microglobulin (n, %) | 79 (24.4) | 33 (29.7) | 29 (19.1) | 17 (27.9) | 0.007 |
| Bulky mass (n, %) | 26 (8.0) | 11 (9.9) | 11 (7.2) | 4 (6.6) | 0.66 |
| Bone marrow involvement (n, %) | 156 (48.1) | 51 (45.9) | 70 (46.1) | 35 (57.4) | 0.07 |
| Nodal site ≥ 5 (n, %) | 143 (44.1) | 44 (39.6) | 64 (42.1) | 35 (57.4) | 0.06 |
| Ann Arbor stage (n, %) | |||||
| I/II | 71 (21.9) | 22 (19.8) | 39 (25.7) | 10 (16.4) | 0.27 |
| III/IV | 253 (78.1) | 89 (80.2) | 113 (74.3) | 51 (83.6) | |
| FLIPI (n, %) | |||||
| Low risk (0-1) | 129 (39.8) | 41 (36.9) | 69 (45.4) | 19 (31.1) | 0.22 |
| Intermediate risk (2) | 114 (35.2) | 37 (33.3) | 52 (34.2) | 25 (41.0) | |
| High risk (3-5) | 81 (25.0) | 33 (29.7) | 31 (20.4) | 17 (27.9) | |
| Grade (n, %) | |||||
| 1 | 163 (50.3) | 34 (30.6) | 100 (65.8) | 29 (47.5) | <0.001 |
| 2 | 68 (21.0) | 16 (14.4) | 33 (21.7) | 19 (31.1) | |
| 3a | 93 (28.7) | 61 (55.0) | 19 (12.5) | 13 (21.3) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase FLIPI, Follicular Lymphoma International Prognostic Index.